Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 4.23%, reaching $7.827 per share, with a total market capitalization of $371 million as of August 19 [1] Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company was 11.311 million RMB, showing a significant year-on-year decline of 64.04% [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

Core Insights - Zhengye Biological (ZYBT) opened with a 3.17% increase, trading at $7.80 per share, with a total market capitalization of $370 million [1] - The company reported total revenue of 186 million RMB for the year ending December 31, 2024, representing a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company was 11.31 million RMB, reflecting a significant year-on-year decline of 64.04% [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

Core Viewpoint - Zhengye Biology (ZYBT) experienced a significant stock price increase of 20.82%, reaching $6.5 per share, with a total market capitalization of $308 million as of August 13 [1] Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The company's net profit attributable to shareholders was 11.31 million RMB, showing a substantial decline of 64.04% year-on-year [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 5.28% on August 12, reaching $5.485 per share, with a total market capitalization of $260 million [1]. Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1]. - The net profit attributable to the parent company was 11.31 million RMB, showing a significant decline of 64.04% compared to the previous year [1]. Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1]. - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1].

Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 4.4% on August 8, reaching $5.69 per share, with a total market capitalization of $270 million [1]. Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1]. - The net profit attributable to the parent company was 11.31 million RMB, showing a significant decline of 64.04% year-on-year [1]. Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that primarily operates through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1]. - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1].

Core Insights - Zhengye Biological (ZYBT) experienced a 5.87% increase in stock price, reaching $5.77 per share with a total market capitalization of $273 million as of August 7 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is expected to be 11.31 million RMB, showing a significant decline of 64.04% year-on-year [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

Core Insights - Zhengye Biological (ZYBT) experienced a 3.67% increase in stock price, reaching $5.65 per share with a total market capitalization of $26.8 million as of August 7 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is expected to be 11.31 million RMB, showing a significant decline of 64.04% year-on-year [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

Group 1 - The core viewpoint of the article highlights the recent stock performance of Zhengye Biological (ZYBT), which saw an increase of 4.91% to $5.56 per share, with a total market capitalization of $263 million as of August 5 [1] - Financial data indicates that Zhengye Biological's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, representing a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is reported at 11.31 million RMB, reflecting a significant year-on-year decline of 64.04% [1] Group 2 - Zhengye Biological Holdings Limited is registered in the Cayman Islands and primarily operates through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]